Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2016
Event: Entry into a Material Definitive Agreement involving the issuance of convertible promissory notes to fund research and development activities.
Key Financial Metrics
This filing does not provide standard financial statements (revenue, profit, cash flow, or margins). The primary financial data points disclosed are:
- Debt Issuance: Two convertible promissory notes issued totaling $1,200,000 ($600,000 each).
- Interest Rate: 8.5% per annum.
- Maturity Date: December 31, 2016.
- Conversion Price: $1.00 per share.
- Collateral: Notes are secured by all of the Company's assets.
- Liquidity Impact: Proceeds are restricted for essential research and development activities.
Material Changes
The filing reports a material change in the company's capital structure and obligations:
- New Debt Obligation: The company incurred $1.2 million in short-term debt due within two months of the filing date.
- Compensation Deferral: Management agreed to defer 20% of earned compensation until the company receives cumulative funding of at least $5,000,000 from non-current stockholders.
- Equity Dilution Risk: Notes are convertible into common stock at $1.00 per share, either at the holder's discretion or automatically upon maturity if unpaid.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: The company intends to use the proceeds strictly to prioritize operations on essential research and development activities.
Contingencies and Triggers:
- Automatic Conversion: If the notes are not paid by December 31, 2016, they will automatically convert to common stock at $1.00 per share.
- Financing Trigger: If the company completes a financing resulting in gross proceeds of at least $5,000,000, the note holders must convert their notes into the same securities issued in that financing at the same price per share.
Risks:
- Liquidity Risk: The short maturity date (December 31, 2016) creates immediate pressure to either repay the debt or secure additional equity financing to trigger conversion.
- Asset Security: All company assets are pledged as security for these notes.
Investor Verification Checklist
- Verify the company's current cash position to assess the ability to repay the $1.2 million debt by December 31, 2016.
- Confirm the status of any ongoing fundraising efforts to reach the $5,000,000 threshold required to trigger mandatory conversion or release management compensation.
- Review the full text of Exhibits 10.1 and 10.2 for specific covenants or additional terms not summarized in the 8-K.
- Assess the potential dilution impact if the notes convert at the $1.00 per share price.